Research ArticleOriginal Article
Open Access

Autoimmune diseases and their prevalence in Saudi Arabian patients with type 1 diabetes mellitus

Walaa M. Mohammedsaeed and Zain J. Alghamdi
Saudi Medical Journal August 2023, 44 (8) 751-760; DOI: https://doi.org/10.15537/smj.2023.44.8.20230240

References

  1. 1.↵
    American Diabetes Association. Standards of medical care in diabetes-2017 abridged for primary care providers. [Updated 2017; Accessed 2021 June 10]. Available from: https://diabetesjournals.org/clinical/article/35/1/5/35446/Standards-of-Medical-Care-in-Diabetes-2017
  2. 2.↵
    International Diabetes Federation. IDF diabetes atlas 6th edition. (2013). [Updated 2013; Accessed 2021 June 11]. Available from: https://idf.org/e-library/epidemiology-research/diabetes-atlas/19-atlas-6th-edition.html
  3. 3.↵
    1. Melmed S,
    2. Polonsky KS,
    3. Larsen PR
    , Kronenberg HM: Williams textbook of endocrinology. Elsevier, Philadelphia, PA; 2011.
  4. 4.↵
    1. Al-Herbish AS,
    2. El-Mouzan MI,
    3. Al-Salloum AA,
    4. Al-Qurachi MM,
    5. Al-Omar AA.
    Prevalence of type 1 diabetes mellitus in Saudi Arabian children and adolescents. Saudi Med J 2008; 29: 1285–1288.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Ghandoora MM,
    2. Almutairi HA,
    3. Alsharef HA,
    4. Habis HM,
    5. Mugharbal EO,
    6. Albogami AM.
    Type 1 diabetes mellitus among pediatrics and adolescents in Saudi Arabia: a systematic review. Int J Adv Res 2017; 5: 2320–5407.
    OpenUrl
  6. 6.↵
    1. Soresi M,
    2. Amplo M,
    3. Agliastro R,
    4. Sesti R,
    5. Di Giovanni G,
    6. Magliarisi C,
    7. Belvedere M,
    8. Carroccio A,
    9. Montalto G.
    Screening for autoantibodies to tissue transglutaminase reveals a low prevalence of celiac disease in blood donors with cryptogenic hypertransaminasemia. Digestion 2001; 64: 87–91.
    OpenUrlPubMed
  7. 7.↵
    1. Marcelino M,
    2. Castro S,
    3. Santos A,
    4. Amaral D
    , PinaR, Lopes L. Prevalence of autoimmune diseases in a type 1 diabetic population. Endocr Abstr 2012; 29: 521.
    OpenUrl
  8. 8.
    1. Karavanaki K,
    2. Kakleas K,
    3. Paschali E,
    4. Kefalas N,
    5. Konstantopoulos I,
    6. Petrou V, et al.
    Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm Res 2009; 71: 201–206.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Gutch M,
    2. Kumar S,
    3. Saran S,
    4. Gupta KK,
    5. Razi SM,
    6. Philip R.
    Prevalence of autoimmune disorders in pediatrics type-1 diabetes mellitus in western, Uttar Pradesh, India. Int J Med Public Heal 2015; 5: 29–31.
    OpenUrl
  10. 10.↵
    1. Alves C,
    2. Santos LS,
    3. Toralles MB.
    Association of type 1 diabetes mellitus and autoimmune disorders in Brazilian children and adolescents. Indian J Endocrinol Metab 2016; 20: 381–386.
    OpenUrl
  11. 11.↵
    1. Al-Hakami AM.
    Pattern of thyroid, celiac, and anti-cyclic citrullinated peptide autoantibodies coexistence with type 1 diabetes mellitus in patients from Southwestern Saudi Arabia. Saudi Med J 2016; 37: 386–391.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Al-Agha AE,
    2. Alafif MM,
    3. Abd-Elhameed IA.
    Glycemic control, complications, and associated autoimmune diseases in children and adolescents with type 1 diabetes in Jeddah, Saudi Arabia. Saudi Med J 2015; 36: 26–31.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Babiker AM,
    2. Issa SD,
    3. Hamza SM,
    4. Otaibi HM,
    5. Jurayyan NA.
    Screening for autoimmune diseases in type 1 diabetes: low incidence of adrenal insufficiency. J Taibah Univ Med Sci 2014; 9: 224–227.
    OpenUrl
  14. 14.↵
    1. Issa SD,
    2. Jurayyan NA,
    3. Aljurayyan AN,
    4. Babiker AM,
    5. Otaibi HM,
    6. Assiri AM.
    Celiac disease associated with type 1 diabetes mellitus in children and adolescents. Eur J Pharm Med Res 2016; 3: 89–92.
    OpenUrl
  15. 15.↵
    1. Alghamdi RA,
    2. Alghamdi AH
    , Fureeh AA: Sero-prevalence of celiac disease among symptom-free type 1 diabetes mellitus in Al-Baha Region, Saudi Arabia. J Pharm Biol Sci 2018; 13: 22–26.
    OpenUrl
  16. 16.↵
    1. Alibrahim AR,
    2. Al-Saleh YM,
    3. Basahih TO,
    4. Bukhari AR,
    5. Alqahtani AA,
    6. Alqahtani M, et al.
    The prevalence of associated autoimmune diseases among adults with type 1 diabetes mellitus: a cross-sectional study. Cureus 2022; 14: e27190.
    OpenUrl
  17. 17.↵
    1. Rohlfing CL,
    2. Wiedmeyer HM,
    3. Little RR,
    4. England JD,
    5. Tennill A,
    6. Goldstein DE.
    Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25: 275–278.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    The National Institutes of Health. National institute on aging’s guidance. [Updated 2022; Accessed 2021 May 17]. Available for: https://www.nia.nih.gov/
  19. 19.↵
    1. Robert AA,
    2. Al-Dawish A,
    3. Mujammami M,
    4. Dawish MAA.
    Type 1 diabetes mellitus in Saudi Arabia: A soaring epidemic. Int J Pediatr 2018; 8: 9408370.
    OpenUrl
  20. 20.↵
    1. Aljabri KS,
    2. Bokhari SA,
    3. Alqurashi K.
    The prevalence of autoantibodies in Saudi patients with type 1 diabetes mellitus. Open J Endocr Metab Dis 2013; 3: 132–136.
    OpenUrl
  21. 21.↵
    1. Al-Agha A,
    2. Ocheltree A,
    3. Hakeem A.
    Thyroid dysfunction in children and adolescents with type 1 diabetes mellitus. J Pediatr Sci 2011; 3: 1–5.
    OpenUrl
  22. 22.↵
    1. Bonifacio E,
    2. Mayr A,
    3. Knopff A,
    4. Ziegler AG.
    Endocrine autoimmunity in families with type 1 diabetes: frequent appearance of thyroid autoimmunity during late childhood and adolescence. Diabetologia 2009; 52: 185–192.
    OpenUrl
  23. 23.↵
    1. Sharifi F,
    2. Ghasemi L,
    3. Mousavinasab N.
    Thyroid function and anti-thyroid antibodies in Iranian patients with type 1 diabetes mellitus: influences of age and sex. Iran J Allergy Asthma Immunol 2008; 7: 31–36.
    OpenUrlPubMed
  24. 24.↵
    1. Saadah OI,
    2. Al-Agha AE,
    3. Al Nahdi HM,
    4. Bokhary RY,
    5. Bin Talib YY,
    6. Al-Mughales JA, et al.
    Prevalence of celiac disease in children with type 1 diabetes mellitus screened by anti-tissue transglutaminase antibody from Western Saudi Arabia. Saudi Med J 2012; 33: 541–546.
    OpenUrlPubMed
  25. 25.↵
    1. Sakly W,
    2. Bienvenu F,
    3. Peretti N,
    4. Lachaux A,
    5. Morel S,
    6. Bouvier R, et al.
    IgA anti-transglutaminase antibodies as a tool for screening atypical forms of coeliac disease in a French at-risk paediatric population. Eur J Gastroenterol Hepatol 2005; 17: 235–239.
    OpenUrlPubMed
  26. 26.↵
    1. Barera G,
    2. Bonfanti R,
    3. Viscardi M,
    4. Bazzigaluppi E,
    5. Calori G,
    6. Meschi F, et al.
    Occurrence of celiac disease after onset of type 1 diabetes: a 6-year prospective longitudinal study. Pediatrics 2002; 109: 833–838.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Triolo TM,
    2. Armstrong TK,
    3. McFann K,
    4. Yu L,
    5. Rewers MJ,
    6. Klingensmith GJ, et al.
    Additional autoimmune disease found in 33% of patients at type 1 diabetes onset. Diabetes Care 2011; 34: 1211–1213.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Crone J,
    2. Rami B,
    3. Huber WD,
    4. Granditsch G,
    5. Schober E.
    Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003; 37: 67–71.
    OpenUrlCrossRefPubMed
  29. 29.
    1. Premawardhana LD,
    2. Wijeyaratne CN,
    3. Chen S,
    4. Wijesuriya M,
    5. Illangasekera U,
    6. Brooking H,
    7. Amoroso M,
    8. Jeffreys J,
    9. Bolton J,
    10. Lazarus JH,
    11. Furmaniak J,
    12. Rees Smith B.
    Islet cell, thyroid, adrenal and celiac disease related autoantibodies in patients with Type 1 diabetes from Sri Lanka. J Endocrinol Invest 2006; 29: 968–974.
    OpenUrlPubMedWeb of Science
  30. 30.↵
    1. Brewer KW,
    2. Parziale VS,
    3. Eisenbarth GS.
    Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 1997; 337: 202.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Babiker A,
    2. Leach ER,
    3. Datta V.
    Should we screen children with type 1 diabetes for Addison’s disease? Arch Dis Child 2011; 96: 700–701.
    OpenUrlFREE Full Text
  32. 32.↵
    1. Marks SD,
    2. Girgis R,
    3. Couch RM.
    Screening for adrenal antibodies in children with type 1 diabetes and autoimmune thyroid disease. Diabetes Care 2003; 26: 3187–3188.
    OpenUrlFREE Full Text
  33. 33.↵
    1. Betterle C,
    2. Greggio NA,
    3. Volpato M.
    Clinical review 93: autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1998; 83: 1049–1055.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Lankisch TO,
    2. Jaeckel E,
    3. Strassburg CP.
    The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin Liver Dis 2009; 29: 307–314.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Neufeld M,
    2. Maclaren NK,
    3. Blizzard RM.
    Two types of autoimmune Addison’s disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60: 355–362.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Ahonen P,
    2. Myllärniemi S,
    3. Sipilä I,
    4. Perheentupa J.
    Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829–1836.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Dailey GE,
    2. Gao L,
    3. Aurand L,
    4. Garg SK.
    Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. Diabetes Obes Metab 2013; 15: 1085–1092.
    OpenUrl
  38. 38.↵
    1. Bolotskaya LL,
    2. Bessmertnaya EG,
    3. Shestakova MV,
    4. Shamkhalova MS,
    5. Nikankina LV,
    6. Ilyin AV, et al.
    [A 20-year prospective follow-up study to evaluate the development of retinopathy and nephropathy after the onset of type 1 diabetes mellitus: contribution of glycemic control and metabolic memory]. Ter Arkh 2017; 89: 17–21. [In Russian]
    OpenUrl
  39. 39.
    1. Soedamah-Muthu SS,
    2. Fuller JH,
    3. Mulnier HE,
    4. Raleigh VS,
    5. Lawrenson RA,
    6. Colhoun HM.
    High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 2006; 29: 798–804.
    OpenUrlAbstract/FREE Full Text
  40. 40.
    1. Lind M,
    2. Svensson AM,
    3. Kosiborod M,
    4. Gudbjörnsdottir S,
    5. Pivodic A,
    6. Wedel H, et al.
    Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972–1982.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Costacou T,
    2. Edmundowicz D,
    3. Prince C,
    4. Conway B,
    5. Orchard TJ.
    Progression of coronary artery calcium in type 1 diabetes mellitus. Am J Cardiol 2007; 100: 1543–1547.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Winocour PH,
    2. Durrington PN,
    3. Ishola M,
    4. Anderson DC,
    5. Cohen H.
    Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987; 294: 1648–1651.
    OpenUrlAbstract/FREE Full Text
  43. 43.
    1. Conway B,
    2. Costacou T,
    3. Orchard T.
    Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes? Diab Vasc Dis Res 2009; 6: 223–230.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords